Clinical Trial

On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06503211
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Enrollment 10 participants
Start Date 2024-07-31
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-16